Genmab — November 2017
-
@McJean: Jeg er enig med dig. Du skal dog huske på, at ikke alle hér i chatten er langsigtede investorer, derfor bliver argumenterne blandet sammen som pærer og bananer

-
Alternativt skulle der køre 2 chat-fora (ell. 3) for hhv. short-, swing- og longtraders.
-
Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer Virginia Powers, PhD,
OncLive, Nov 07, 2017 - http://www.onclive.com/conference-coverage/esgo-2017/tisotumab-vedotin-shows-clinical-benefit-and-ongoing-responses-in-cervical-cancer -
Regnskabet er nok i sig selv en non-event, men tror Jan får en del spørgsmål angående salget..........og hvis ikke han er klar i spyttet her, så tænker jeg også ned i morgen. Af dårlige ting i regnskabet kunne være fase III data for ofatumumab i FL. Desuden skal vi også snart have de to IND´er på banen - ville være noget af en bet, hvis en af dem forsinkes betydeligt eller helt udebliver
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
